MedTrace Logo

Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids

NCT01027143 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2023-09-08

Study results available
· View outcomes & findings →

Summary

This project will assess the effectiveness of omega-3 fatty acid supplementation in controlling asthma symptoms among obese asthmatics, and will assess if a person's genes influence response to treatment (personalized medicine). This project may improve our ability to treat asthma and our understanding of the link between obesity and asthma.

Conditions

Interventions

DIETARY_SUPPLEMENT

omega-3 polyunsaturated fatty acids

ProEPA Xtra 1000mg softgels: 3 softgels twice daily

DRUG

Omega-3 Fatty Acid

Soybean oil: 3(age 12-25) matched softgel caps twice daily

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Office of Dietary Supplements (ODS)

    collaborator NIH

  • Nemours Children's Clinic

    lead OTHER

Principal Investigators

  • Jason E. Lang, M.D. · Duke Children's Hospital and Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2016-10-22
Completion
2016-10-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01027143 on ClinicalTrials.gov